CVRx to Present at the William Blair 42nd Annual Growth Stock Conference

Rhea-AI Summary

CVRx, a medical device company, will present at the William Blair 42nd Annual Growth Stock Conference on June 6, 2022, at 3:20 pm Central Time. The presentation will be available via webcast on the company's investor relations page. CVRx is known for Barostim™, the first FDA-approved neuromodulation technology for heart failure, which delivers electrical pulses to carotid artery baroreceptors to restore autonomic balance and alleviate symptoms. Barostim has received both FDA Breakthrough Device designation and the CE Mark for heart-related conditions.

MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022. The Company is scheduled to present at 3:20 pm Central Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. A replay of the webcast will be archived on the website for approximately 90 days.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com 

Media Contact:

Erich Sandoval
Finn Partners
212-867-1762
erich.sandoval@finnpartners.com 

FAQ

When is CVRx presenting at the William Blair 42nd Annual Growth Stock Conference?

CVRx will present on June 6, 2022, at 3:20 pm Central Time.

Where can I watch the CVRx presentation live?

The live presentation can be viewed on CVRx's investor relations page.

What is Barostim from CVRx?

Barostim is the first FDA-approved neuromodulation device designed to improve heart failure symptoms by delivering electrical pulses to baroreceptors in the carotid artery.

What designations has Barostim received?

Barostim has received FDA Breakthrough Device designation and the CE Mark for heart failure and resistant hypertension.

How long will the CVRx webcast be available for replay?

The replay of the CVRx webcast will be archived for approximately 90 days.